Key result
Switching to rosuvastatin and ezetimibe is linked to ~71% of stroke patients achieving LDL-C under 70 mg/dL.
Why the study?
Many stroke patients fail to achieve target LDL-C levels with statin monotherapy, necessitating real-world evaluation of switching to rosuvastatin plus ezetimibe.
Does switching to rosuvastatin plus ezetimibe improve LDL-C target achievement in stroke patients with LDL-C ≥ 70 mg/dL on statin monotherapy?
Observational (n=1,431)
Open-label
Yes
Does switching to rosuvastatin plus ezetimibe improve LDL-C target achievement in stroke patients with LDL-C ≥ 70 mg/dL on statin monotherapy?
Switching from statin monotherapy to rosuvastatin plus ezetimibe effectively reduces LDL-C to target levels (<70 mg/dL) in over 70% of stroke patients in real-world practice.
May support real-world LDL-C intensification in stroke; leaves open randomized confirmation of outcomes.
Effective lipid management is critical for secondary stroke prevention, however, many patients fail to achieve target low-density lipoprotein cholesterol (LDL-C) levels with statin monotherapy. This study evaluated the real-world effectiveness and safety of switching from statin monotherapy to rosuvastatin plus ezetimibe combination therapy (REZ) in patients with stroke. This multicenter, prospective, observational study enrolled patients with stroke and baseline LDL-C ≥ 70 mg/dL despite statin monotherapy from 16 Korean stroke centers. Participants were switched to REZ at doses of 5/10 mg, 10/10 mg, or 20/10 mg at the investigators’ discretion. Lipid profiles were assessed at three and six months. The primary outcome was achieving LDL-C < 70 mg/dL at six months. In total, 1,431 participants enrolled between May 2021 and March 2023 were eligible (mean age 65.3 ± 10.6 years; 66.8% male). Among 994 participants completing follow-up, the mean baseline LDL-C was 98.9 ± 22.4 mg/dL. At six months, 708 (71.2%) achieved LDL-C < 70 mg/dL. Mean LDL-C decreased to 62.7 ± 22.1 mg/dL at three months and to 62.0 ± 22.0 mg/dL at six months. The effectiveness of REZ remained consistent across different REZ dosages and regardless of changes in statin intensity during the switch. REZ was particularly effective in patients with diabetes (odds ratio [95% confidence interval], 1.85 [1.32–2.59]; P < 0.001) and baseline LDL-C 70–99 mg/dL (2.71 [2.04–3.59]; P < 0.001). Fewer participants achieved stricter targets (LDL-C < 55 mg/dL or LDL-C < 70 mg/dL plus 50% reduction). Switching to REZ effectively reduced LDL-C in patients with stroke receiving statin monotherapy with LDL-C ≥ 70 mg/dL, offering potential benefits for secondary cardiovascular prevention in real-world practice.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted an observational in Stroke with LDL-C ≥ 70 mg/dL despite statin monotherapy (n=1,431). Rosuvastatin plus ezetimibe combination therapy vs. Prior statin monotherapy (baseline) was evaluated on Achieving LDL-C < 70 mg/dL at six months (95% CI 68.3-74.0). Switching to rosuvastatin plus ezetimibe combination therapy enabled 71.2% of stroke patients with suboptimal LDL-C on statin monotherapy to achieve LDL-C < 70 mg/dL at six months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: